South San Francisco-based Lyell Immunopharma , Inc., currently valued at $178 million by market capitalization, has been notified by Nasdaq of non-compliance with the minimum bid price requirement, as ...

BofA lowered the firm’s price target on Lyell Immunopharma (LYEL) to 60c from $1 and keeps an Underperform rating on the shares. The firm said on Friday that Lyell provided a business update ...

Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders Using data ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Lyell Immunopharma (LYEL – Research Report), with a price target of $1.00. The company’s ...